Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.96 |
| ▸ | PPARD | Q03181 | 5/20 | 0.96 |
| ▸ | PPARA | Q07869 | 5/20 | 0.96 |
| ▸ | F7 | P08709 | 5/20 | 0.96 |
| ▸ | F3 | P13726 | 5/20 | 0.96 |
| ▸ | TERT | O14746 | 3/20 | 0.96 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.96 |
| ▸ | TOP1 | P11387 | 3/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.96 |
| ▸ | FABP4 | P15090 | 3/20 | 0.96 |
| ▸ | MAPT | P10636 | 2/20 | 0.96 |
| ▸ | BLM | P54132 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.96 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.96 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.96 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.96 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26624690 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL3614606 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL7588991 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL6112723 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL5370158 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL5394778 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL5394776 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL6119144 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL3620764 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL26624682 | 1.00 | PPARG (0.96) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018085-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | BIOJIVA LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018085-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | BIOJIVA LLC | 2024-01-18 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210387938-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | RETROTOPE, INC. | 2021-12-16 | — | — | US | disclosed |
| US-11166930-B2 | Isotopically modified components and therapeutic uses thereof | RETROTOPE, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210331998-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | RETROTOPE, INC. | 2021-10-28 | — | — | US | disclosed |
| EP-3380452-B1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1, 4-DIENE SYSTEMS | RETROTOPE INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10730821-B2 | Site-specific isotopic labeling of 1,4-diene systems | RETROTOPE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200129467-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | RETROTOPE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20070066170-A1 | CO2 GENERATING ABSORBENT PADS | CO2 TECHNOLOGIES, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-7189666-B2 | CO2 generating absorbent pads | CO2 TECHNOLOGIES (US) | 2007-03-13 | — | — | US | disclosed |
| US-7160939-B2 | Preservatives; mixture of carbon dioxide in polymer matrix; mixture containing citric acid, calcium carbonate and low density polyethylene | CO2 TECHNOLOGIES, INC. | 2007-01-09 | — | — | US | disclosed |
| WO-2005005520-A2 | ACTIVE MASTERBATCH FOR PRODUCTION OF CO2 GENERATING MASTERBATCH | CO2 TECHNOLOGIES, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050001204-A1 | Active masterbatch for production of CO2 generating masterbatch | CO2 TECHNOLOGIES, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| WO-2004110876-A2 | CO2 GENERATING ABSORBENT PADS | CO2 TECHNOLOGIES, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040247750-A1 | CO2 generating absorbent pads | CO2 TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| US-6797235-B2 | Device and methods for modifying an atmosphere | CO2 TECHNOLOGIES, INC. | 2004-09-28 | — | — | US | disclosed |
| WO-2004022112-A1 | DEVICE AND METHODS FOR MODIFYING AN ATMOSPHERE | CO2 TECHNOLOGIES, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-20040047760-A1 | Device and methods for modifying an atmosphere | LONGER SHELF LIFE, LLC | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387938-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | FADS1, FASN, FADS2 | PPARG 53/4885PPARD 58/4885PPARA 59/4885 |
| US-20240018085-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | FADS1, FASN, FADS2 | PPARG 53/4885PPARD 58/4885PPARA 59/4885 |
| US-20200129467-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | GPX4, ALOX12, ALOX15 | PPARG 40/4885PPARD 69/4885PPARA 67/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | PPARG 159/4885PPARD 334/4885PPARA 110/4885 |
| US-10730821-B2 | Site-specific isotopic labeling of 1,4-diene systems | FADS1, FASN, FADS2 | PPARG 53/4885PPARD 58/4885PPARA 59/4885 |
| US-20210331998-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | FADS1, FASN, FADS2 | PPARG 53/4885PPARD 58/4885PPARA 59/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | PPARG 289/4885PPARD 221/4885PPARA 215/4885 |
| US-11166930-B2 | Isotopically modified components and therapeutic uses thereof | ACADM, ALDH2, CPT1A | PPARG 249/4885PPARD 213/4885PPARA 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.